Freddy A. Jimenez

CIK: 0001838114

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (60.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CLDX

Celldex Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

CLDX
Celldex Therapeutics, Inc.
Jun 25, 2026
Award(A)
Incentive Stock Option (right to buy)
Direct
93K shares-
CLDX
Celldex Therapeutics, Inc.
Dec 4, 2025
Sale(S)
Direct
4.2K shares at avg. $29.09$121K
CLDX
Celldex Therapeutics, Inc.
Aug 13, 2025
Sale(S)
Direct
341 shares at avg. $23.95$8K
CLDX
Celldex Therapeutics, Inc.
Aug 13, 2025
Sale(S)
Direct
430 shares at avg. $25.41$11K
CLDX
Celldex Therapeutics, Inc.
Jun 5, 2025
Award(A)
Incentive Stock Option (right to buy)
Direct
75K shares-

		Type	Shares	Price		Ownership
Jun 25, 2026	CLDX Celldex Therapeutics, Inc.	Award(A) Incentive Stock Option (right to buy)	93,000	-	-	Direct
Dec 4, 2025	CLDX Celldex Therapeutics, Inc.	Sale(S)	4,166	$29.09	$121,210	Direct
Aug 13, 2025	CLDX Celldex Therapeutics, Inc.	Sale(S)	341	$23.95	$8,167	Direct
Aug 13, 2025	CLDX Celldex Therapeutics, Inc.	Sale(S)	430	$25.41	$10,928	Direct
Jun 5, 2025	CLDX Celldex Therapeutics, Inc.	Award(A) Incentive Stock Option (right to buy)	75,000	-	-	Direct

1-5 of 5 transactions

About Jimenez Freddy A.

Jimenez Freddy A. (SEC CIK 0001838114) files insider reports with the SEC as SVP & GENERAL COUNSEL of Celldex Therapeutics, Inc. (CLDX).

Signal8 holds 4 ownership filings by Jimenez Freddy A., all Form 4s, filed between Jun 9, 2025 and Jun 29, 2026. Those filings report 5 transactions, from Jun 5, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Jimenez Freddy A.'s filings is in HAMPTON, NJ.

Recent filings by Jimenez Freddy A.

Jun 25, 2026: Grant or award of CLDX derivative securities (Form 4, code A).
Dec 4, 2025: Open-market sale of CLDX shares (Form 4, code S).
Aug 13, 2025: Open-market sales of CLDX shares (2 lines, Form 4, code S).
Jun 5, 2025: Grant or award of CLDX derivative securities (Form 4, code A).

Other insiders filing for Celldex Therapeutics, Inc. (CLDX)

Lawver Teri L, SVP & Chief Commercial Officer
Young Diane C., SVP, CHIEF MEDICAL OFFICER
Heath-Chiozzi Margo, SVP OF REGULATORY AFFAIRS
Martin Samuel Bates, SVP AND CFO
Cavanaugh Sarah, SVP OF CORP AFFAIRS & ADMIN.
Crowley Elizabeth, SR. VP & CPDO

How to read Form 4 transaction codes